Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food-effect of ACCG-2671

NCT07815678 is registered in ClinicalTrials.gov with Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics as lead sponsor.

NCT NCT07815678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07815678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food-effect of ACCG-2671
Lead sponsor
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 29, 2025
Completion date
April 30, 2027
Enrollment
164 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

obesity